Imatinib Solubility

Imatinib Mesylate

I031-100MG 100 mg
EUR 124

Imatinib Mesylate

I031-25MG 25 mg
EUR 63

Imatinib (Mesylate)

HY-50946 5g
EUR 318

Imatinib Mesylate

E1KS1026 250mg
EUR 247

Imatinib (Gleevec)

E1KS2475 250mg
EUR 325

Imatinib mesylate

20-abx076675
  • EUR 384.00
  • EUR 244.00
  • 100 mg
  • 20 mg

Imatinib hydrochloride

A3487-100 100 mg
EUR 131
Description: Description:IC50 Value: 100 nM (PDGFR) [1]; 100 nM (c-Kit) [2]Imatinib is a multi-target inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 ?M, 0.1 ?M and 0.1 ?M, respectively.

Imatinib (STI571)

B2171-100 100 mg
EUR 131
Description: Imatinib is an inhibitor of protein-tyrosine kinase with IC50 values of 0.1, 0.1 and 0.025?M, respectively against PDGF receptor, c-Kit and Abl [1].

Imatinib (STI571)

B2171-5.1 10 mM (in 1mL DMSO)
EUR 108
Description: Imatinib is an inhibitor of protein-tyrosine kinase with IC50 values of 0.1, 0.1 and 0.025?M, respectively against PDGF receptor, c-Kit and Abl [1].

Imatinib . mesylate

10-028 250 mg
EUR 392.6
Description: Imatinib mesylate is a multitarget tyrosine kinase inhibitor with antineoplastic activity. It is a potent and selective inhibitor of the kinases Bcr-Abl (IC50 = 38 nM), PDGFR and c-Kit, which are encoded by the bcr-abl oncogene as well as receptor tyrosine kinases encoded by c-Kit and platelet-derived growth factor receptor (PDGFR) oncogenes, which is useful in vitro and in vivo. Imatinib inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit and the proliferation of Bcr-Abl-dependent R10 cells and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner. Formulations containing imatinib have been used in the treatment of various cancers. Specifically, it is used for chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL) that are Philadelphia chromosome-positive (Ph+), certain types of gastrointestinal stromal tumors (GIST), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), systemic mastocytosis and myelodysplastic syndrome. Abelson (Abl) kinase inhibitors have been shown to inhibit replication of Ebola virus, coxsackievirus and vaccinia virus, but at different points of the virus life cycle. Imatinib inhibits replication of SARS-CoV and MERS-CoV in vitro by a novel mechanism of blocking coronavirus virion fusion with the endosomal membrane. Abl is also a potential drug target of SARS-CoV-2 and can possible inhibit the spread of COVID-19.

Imatinib Mesylate (STI571)

A1805-5.1 10 mM (in 1mL DMSO)
EUR 119
Description: Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively [1].Tyrosine kinase is an enzyme which is a subclass of protein kinase and plays an important role in transferring a phosphate group from ATP to a protein in cells.

Imatinib Mesylate (STI571)

A1805-S Evaluation Sample
EUR 81
Description: Imatinib mesylate is a tyrosine kinase inhibitor IC50 value of 100 nM, 100 nM, 600 nM for v-Abl, c-kit, PDGFR, respectively [1].Tyrosine kinase is an enzyme which is a subclass of protein kinase and plays an important role in transferring a phosphate group from ATP to a protein in cells.

Imatinib, Free base

2141-100
EUR 147

Imatinib, Free base

2141-1000
EUR 419

Imatinib, Methanesulfonate Salt, >99%

BC040-101 1g
EUR 232

Imatinib, Methanesulfonate Salt, >99%

BC040-102 2g
EUR 300

Imatinib, Methanesulfonate Salt, >99%

BC040-105 5g
EUR 421

Imatinib, Methanesulfonate Salt, >99%

BC040-500 500mg Ask for price

Imatinib mesylate (Kinase inhibitor)

SIH-453-100MG 100 mg
EUR 233
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

Imatinib mesylate (Kinase inhibitor)

SIH-453-20MG 20 mg
EUR 126
Description: The substance Imatinib mesylate is a kinase inhibitor. It is synthetically produced and has a purity of ?98%. The pure substance is white to beige solid which is soluble H2O: soluble10 mg/ml, clear .

Imatinib Mesylate (CGP-57148B, STI-571)

1625-100
EUR 156

Imatinib Mesylate (CGP-57148B, STI-571)

1625-1000
EUR 436

Imatinib Mesylate (CGP-57148B, STI-571)

1625-5000 Ask for price